AllSci News
HSS researchers uncover hidden driver of rheumatoid arthritis beyond inflammation
Researchers at the Hospital for Special Surgery (HSS) Research Institute in New York have identified a distinct immune cell population that appears to drive...
Optimeos secures backing for non-viral nano gene therapy delivery
Princeton, New Jersey-based Optimeos Life Sciences has announced an investment from Hatch BioFund, an early-stage life sciences venture capital firm...
Otsuka reports positive Phase IIIb anxiety data as centanafadine nears July FDA decision
Otsuka has reported positive Phase IIIb results for centanafadine sustained-release in adults with ADHD and comorbid anxiety, a readout that matters because...
University of Pennsylvania investigates discontinuing anti-CD20 therapy in relapsing MS
The University of Pennsylvania has received a USD 1.34 million NIH U01 award to conduct a randomized, placebo-controlled trial testing whether ocrelizumab...
Epitopea's mRNA vaccine targets ovarian cancer's treatment-resistant majority with first-in-human trial
Epitopea's mRNA cancer vaccine CryptiVax-1001 enters first-in-human testing in ovarian cancer's hardest-to-treat subgroup
HUTCHMED's fanregratinib posts pivotal Phase II data as China NDA enters priority review
HUTCHMED's fanregratinib demonstrated a 42.5% objective response rate in pretreated patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma,...
Mwyngil reports one of the first public in vivo datasets for GPR75 obesity program
Boston-based Mwyngil Therapeutics reported preclinical proof-of-concept data for its GPR75 inverse agonist obesity program, with lead oral compounds...
Lycia raises USD 75m to advance novel extracellular protein degradation into early clinical trials
South San Francisco-based Lycia Therapeutics, Inc., a clinical-stage biotechnology company developing therapeutics designed to degrade disease-causing...
Merck’s Keytruda-Padcev combo becomes first PD-1/ADC regimen for cisplatin-ineligible bladder cancer
The European Commission has approved Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin) as perioperative treatment for adults with resectable muscle-invasive bladder…
Remix Therapeutics takes Nasdaq listing through Passage Bio reverse merger, USD 100m raise
Philadelphia-based Passage Bio (Nasdaq: PASG) and Watertown, Massachusetts-based Remix Therapeutics have announced a definitive all-stock merger agreement...
Eli Lilly doubles down on ProQR with USD 59.2m funding round
Netherlands-based ProQR Therapeutics N.V. (Nasdaq: PRQR) announced the pricing of a combined underwritten registered direct offering and concurrent private...
Taysha raises USD 200m to advance Rett syndrome gene therapy independently after Astellas exit
Dallas-based Taysha Gene Therapies (Nasdaq: TSHA) announced the pricing of an underwritten public offering of common stock and pre-funded warrants, raising...
Oblenio raises USD 62m to test tri-specific T-cell engager in autoimmune disease
Cambridge, Massachusetts-based Oblenio Bio, Inc. has closed an oversubscribed USD 62 million Series B financing round to advance LBL-051, its CD19/BCMA/CD3...
Henlius’ PD-1 Hetronifly adds new indication in 1st-line squamous lung cancer across EU
The European Commission has approved a new indication for Hetronifly (serplulimab), China-based Shanghai Henlius Biotech’s (HKEX: 02696) anti-PD-1 antibody, covering first-line treatment…
CStone completes global rollout of PD-L1 sugemalimab with Australia-New Zealand deal
CStone Pharmaceuticals (HKEX: 2616) has completed its geographic rollout of sugemalimab by signing an exclusive commercialization agreement with Arrotex...
The AllSci Brief
Free, systematic R&D and deal news. Daily.